Carcinoma of the anal canal

David T. Marshall, Charles Thomas

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

There are around 5,000 new cases of anal canal cancer each year in the United States. It is of particular risk in HIV-positive populations. Many cases are related to persistent infection with human papillomavirus (HPV). The treatment of anal cancer has progressed from abdominoperineal resection mandating permanent colostomy in the 1940s through the 1970s to modern chemoradiation with sphincter preservation in around 80% of patients, even with locally advanced disease. The evolution of the treatment paradigm of this disease is a model for the treatment of malignant disease with organ preservation. Multiple randomized trials have been conducted to guide this evolution. Technological developments in the delivery of radiotherapy and anti-cancer pharmaceuticals harbor hope for further improvements in outcomes with possible reductions in toxicity and increases in tumor control. Perhaps most inspiring is the recent development of HPV vaccines that may significantly decrease the incidence of this cancer.

Original languageEnglish (US)
Pages (from-to)27-40
Number of pages14
JournalOncology Reviews
Volume3
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Anus Neoplasms
Organ Preservation
Papillomavirus Vaccines
Neoplasms
Colostomy
Anal Canal
Radiotherapy
Therapeutics
HIV
Incidence
Infection
Pharmaceutical Preparations
Population
Anal Canal Carcinoma

Keywords

  • Anal canal cancer
  • Chemoradiation
  • HPV
  • Organ preservation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Carcinoma of the anal canal. / Marshall, David T.; Thomas, Charles.

In: Oncology Reviews, Vol. 3, No. 1, 2009, p. 27-40.

Research output: Contribution to journalArticle

Marshall, David T. ; Thomas, Charles. / Carcinoma of the anal canal. In: Oncology Reviews. 2009 ; Vol. 3, No. 1. pp. 27-40.
@article{bfada53708b34303b8cb572a195c9709,
title = "Carcinoma of the anal canal",
abstract = "There are around 5,000 new cases of anal canal cancer each year in the United States. It is of particular risk in HIV-positive populations. Many cases are related to persistent infection with human papillomavirus (HPV). The treatment of anal cancer has progressed from abdominoperineal resection mandating permanent colostomy in the 1940s through the 1970s to modern chemoradiation with sphincter preservation in around 80{\%} of patients, even with locally advanced disease. The evolution of the treatment paradigm of this disease is a model for the treatment of malignant disease with organ preservation. Multiple randomized trials have been conducted to guide this evolution. Technological developments in the delivery of radiotherapy and anti-cancer pharmaceuticals harbor hope for further improvements in outcomes with possible reductions in toxicity and increases in tumor control. Perhaps most inspiring is the recent development of HPV vaccines that may significantly decrease the incidence of this cancer.",
keywords = "Anal canal cancer, Chemoradiation, HPV, Organ preservation",
author = "Marshall, {David T.} and Charles Thomas",
year = "2009",
doi = "10.1007/s12156-009-0006-7",
language = "English (US)",
volume = "3",
pages = "27--40",
journal = "Oncology Reviews",
issn = "1970-5557",
publisher = "PagePress",
number = "1",

}

TY - JOUR

T1 - Carcinoma of the anal canal

AU - Marshall, David T.

AU - Thomas, Charles

PY - 2009

Y1 - 2009

N2 - There are around 5,000 new cases of anal canal cancer each year in the United States. It is of particular risk in HIV-positive populations. Many cases are related to persistent infection with human papillomavirus (HPV). The treatment of anal cancer has progressed from abdominoperineal resection mandating permanent colostomy in the 1940s through the 1970s to modern chemoradiation with sphincter preservation in around 80% of patients, even with locally advanced disease. The evolution of the treatment paradigm of this disease is a model for the treatment of malignant disease with organ preservation. Multiple randomized trials have been conducted to guide this evolution. Technological developments in the delivery of radiotherapy and anti-cancer pharmaceuticals harbor hope for further improvements in outcomes with possible reductions in toxicity and increases in tumor control. Perhaps most inspiring is the recent development of HPV vaccines that may significantly decrease the incidence of this cancer.

AB - There are around 5,000 new cases of anal canal cancer each year in the United States. It is of particular risk in HIV-positive populations. Many cases are related to persistent infection with human papillomavirus (HPV). The treatment of anal cancer has progressed from abdominoperineal resection mandating permanent colostomy in the 1940s through the 1970s to modern chemoradiation with sphincter preservation in around 80% of patients, even with locally advanced disease. The evolution of the treatment paradigm of this disease is a model for the treatment of malignant disease with organ preservation. Multiple randomized trials have been conducted to guide this evolution. Technological developments in the delivery of radiotherapy and anti-cancer pharmaceuticals harbor hope for further improvements in outcomes with possible reductions in toxicity and increases in tumor control. Perhaps most inspiring is the recent development of HPV vaccines that may significantly decrease the incidence of this cancer.

KW - Anal canal cancer

KW - Chemoradiation

KW - HPV

KW - Organ preservation

UR - http://www.scopus.com/inward/record.url?scp=67349124185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349124185&partnerID=8YFLogxK

U2 - 10.1007/s12156-009-0006-7

DO - 10.1007/s12156-009-0006-7

M3 - Article

AN - SCOPUS:67349124185

VL - 3

SP - 27

EP - 40

JO - Oncology Reviews

JF - Oncology Reviews

SN - 1970-5557

IS - 1

ER -